Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium–glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus

Documenti analoghi

• Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus
  di: Saito, Masako, et al.
  Pubblicazione: (2020)
• Randomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus
  di: Kashiwagi, Atsunori, et al.
  Pubblicazione: (2013)
• Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin
  di: Choi, Min-Koo, et al.
  Pubblicazione: (2020)
• Effects of ipragliflozin, a selective sodium–glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials
  di: Kashiwagi, Atsunori, et al.
  Pubblicazione: (2016)
• Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials
  di: Kashiwagi, Atsunori, et al.
  Pubblicazione: (2016)